News

Shares of small U.S.-based chip manufacturing start-up SkyWater Technologies (NASDAQ: SKYT) initially tanked over 30% following its Q1 2024 earnings update. Shares have rebounded a bit since then

Space mobility specialist AST SpaceMobile (NASDAQ: ASTS) is formalizing ties with partner AT&T ahead of its commercial launch this summer. That news, along with AST's latest earnings report, has the

The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You

If you'd invested $10,000 in Novavax (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant

Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.

Eli Lilly (NYSE: LLY) and Regeneron

Novavax (NASDAQ: NVAX) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with

Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this

AT&T (NYSE: T) and T-Mobile US (NASDAQ: TMUS) are two of the three major telcos that dominate the U.S. wireless market, but each arrived at that point from different places.

AT&T is a former Baby

After losing more than 90% of its value from a peak back in 2021, Novavax (NASDAQ: NVAX) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion

Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon

There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks

Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global

Investors have enjoyed higher Treasury yields, serving up passive income over the past couple of years. However, there's still an abundance of quality dividend stocks that offer potential price

Many investors hold a stake in AbbVie (NYSE: ABBV) because it offers exposure to the healthcare sector. Industry-based diversification, however, isn't all the pharmaceutical outfit brings to the

Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its

Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to

AI chip leader Nvidia (NASDAQ: NVDA) will no doubt have very strong growth over the next year-plus. But while the chip designers like Nvidia and its would-be competitors garner a lot of headlines

Pfizer (NYSE: PFE) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the

There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity.

However, Vertex

Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field

The stock market has taken investors for a wild ride these last few years. When you're investing in stocks for many years, though, even multiple tough market cycles shouldn't deter you from your

It's a race to the riches in the anti-obesity drug market. This therapeutic area is projected to grow exponentially in the coming years. Novo Nordisk is one of the clear market leaders -- for now --